Difference between revisions of "Hu H, et al, Eur Heart J (2020), cited as Ref 29 in DOI: 10.1007/s11886-020-01293-2 (Q11023)"
Jump to navigation
Jump to search
(Created claim: Third Author string (P151): Wei X, #quickstatements; #temporary_batch_1592835612481) |
(Created claim: Fourth Author string (P152): Fang Y, #quickstatements; #temporary_batch_1592835703983) |
||
| Property / Fourth Author string | |||
| + | Fang Y | ||
| Property / Fourth Author string: Fang Y / rank | |||
| + | Normal rank | ||
Revision as of 14:22, 22 June 2020
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
In more languages
Configure| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Hu H, et al, Eur Heart J (2020), cited as Ref 29 in DOI: 10.1007/s11886-020-01293-2
|
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
|
Statements
Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. First case report describing fulminant viral myocarditis caused by COVID-19 (English)
